Nektar posts Q3 loss as rezpegaldesleukin enters Phase 3
Nektar Therapeutics reported third-quarter 2026 results on November 12, with revenue of $9.39M and a net loss of $55.65M. The company had $952.9M in cash and investments at September 30 and said all three ZENITH AD trials for rezpegaldesleukin in atopic dermatitis had begun. Nektar expects its alopecia areata Phase 3 trial to start in December 2026, with topline atopic dermatitis data expected in 2028.
Why it matters
The results show increased spending as Nektar advances its lead drug into late-stage testing, while the reported cash balance provides funding for those programs. The company expects topline data in 2028 and the first BLA filing in 2029, extending the period before potential product revenue.
Key facts
- 1Third-quarter revenue was $9.39M and the net loss was $55.65M, with higher R&D and G&A expenses contributing to the loss. tradingview.com
- 2Cash and investments totaled $952.9M at September 30, 2026, compared with $245.8M at December 31, 2025. prnewswire.com
- 3Nektar reported a third-quarter basic and diluted net loss of $1.63 per share. prnewswire.com
- 4The company initiated the third and final ZENITH AD registrational trial in October 2026 and expects initial topline data in mid-2028. sec.gov
- 5Nektar said its global ZENITH AA registrational trial for alopecia areata is scheduled to begin in December 2026. prnewswire.com
Open questions
- Materials disagree on the analyst estimate for third-quarter loss per share: $2.08 in material 1 versus $2.16 in material 5; material 6 gives a $0.45 beat based on its estimate.
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.